News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response
A study published in Cancer Cell by Ma et al. has identified a previously unrecognized subset of cancer-associated fibroblasts (CAFs) marked by PTGER3 expression that emerges in response to chemotherapy and exhibits elevated lipid oxidation. These specialized fibroblasts secrete the lipid mediator 11-HETE, which enhances CD8+ T cell killing capacity by suppressing PTEN-related signaling pathways w…
A photoreceptor state links aggressive brain tumors in children
A study published in Cancer Cell by Gudenas and colleagues reveals that three aggressive pediatric cancers — Group 3 medulloblastoma, pineoblastoma, and retinoblastoma — share a common tumor-associated photoreceptor gene signature rooted in transient developmental progenitor cells. The finding fundamentally reframes these distinct malignancies as diseases arising from a shared window of developmen…
Structuring pathology foundation models with domain knowledge
Researchers have developed KEEP, a novel vision-language foundation model for computational pathology that integrates hierarchical disease knowledge into its pre-training process through a structured disease graph. Published in Cancer Cell, the study by Zhou et al. demonstrates that this knowledge-guided approach shapes more meaningful semantic representations, leading to significantly improved ze…
Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders
A study published in Cancer Cell has identified a novel population of PTGER3-positive cancer-associated fibroblasts (CAFs) that emerge specifically in bladder cancer patients who respond to neoadjuvant chemotherapy. These chemotherapy-induced fibroblasts undergo lipid oxidation reprogramming and actively enhance CD8+ T cell function, thereby remodeling the tumor microenvironment and restraining tu…
Hallmarks of cancer—Then and now, and beyond
In a landmark review published in Cell, Douglas Hanahan revisits and expands the influential Hallmarks of Cancer framework, which has shaped oncology research for a quarter-century. The updated synthesis integrates aberrant cellular capabilities, enabling traits, tumor microenvironment dynamics, and systemic host interactions into a multidimensional model of tumorigenesis. Hanahan proposes that me…
Microbiota and immune-related adverse events in cancer immunotherapy
A new Progress article published in Nature Reviews Cancer by Schneider et al. examines the growing body of evidence linking the gut microbiome to the development and progression of immune-related adverse events (irAEs) during cancer immunotherapy. The review synthesizes both clinical and preclinical data demonstrating that specific microbial compositions can influence the risk of complications suc…
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy
A study published in Nature Cancer by Li et al. presents a comprehensive multi-omics analysis of nasopharyngeal carcinoma (NPC), a malignancy most prevalent in Southeast Asia and southern China. The researchers identified three distinct molecular subtypes of NPC, each characterized by unique immune microenvironment profiles and differing responses to induction chemotherapy. These findings could pa…
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177 Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
A substudy of the randomized phase 2 ENZA-p trial, published in Nature Cancer, evaluated the frequency, magnitude, and clinical significance of early prostate-specific membrane antigen (PSMA) upregulation in patients with poor-risk metastatic castration-resistant prostate cancer treated with enzalutamide alone or combined with the radioligand therapy 177Lu-PSMA-617. The findings by Emmett and coll…
This AI spots dangerous blood cells doctors often miss
Researchers have developed a generative AI system capable of analyzing blood cells with greater accuracy and confidence than human experts, including the detection of subtle abnormalities associated with leukemia and other hematologic malignancies. The system not only identifies rare cell morphologies that clinicians may overlook, but also quantifies its own uncertainty, flagging cases where addit…
Scientists discover why cancer drugs don’t work for everyone
Scientists have identified a previously unrecognized mechanism that may explain why cancer treatments produce uneven responses across patients. The research revealed that certain anticancer drugs can become sequestered inside lysosomes within tumor cells, effectively creating slow-release reservoirs that lead to highly uneven drug distribution across the tumor. As a result, some cancer cells recei…